Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Modan

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
Harefuah|November 15, 1981
[Leukocyte adherence inhibition test and carcinoembryonic antigen in colorectal carcinoma]A Shani, Z Weissman, Z Cohen, et al.
The American Journal of Cardiology|February 1, 1991
Prognostic importance of delayed Q-wave evolution 3 to 24 hours after initiation of thrombolytic therapy for acute myocardial infarctionM J Eisenberg, G I Barbash, H Hod, et al.
The American Journal of Cardiology|July 15, 1989
Intermittent, dose-related fluctuations of pain and ST elevation during infusion of recombinant tissue plasminogen activator during acute myocardial infarctionG I Barbash, H Hod, S Rath, et al.
Journal of the American College of Cardiology|April 1, 1990
Should thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot studyA Roth, G I Barbash, H Hod, et al.
British Heart Journal|October 1, 1990
Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial InfarctionG I Barbash, A Roth, H Hod, et al.
The American Journal of Cardiology|December 1, 1989
Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarctionG I Barbash, H Hod, A Roth, et al.
The American Journal of Cardiology|September 1, 1990
Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarctionG I Barbash, A Roth, H Hod, et al.
The American Journal of Cardiology|August 1, 1990
Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarctionG I Barbash, A Roth, H Hod, et al.
Circulation|November 1, 1993
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality StudyH D White, G I Barbash, M Modan, et al.
Archives of Internal Medicine|October 10, 1994
Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality TrialG I Barbash, H D White, M Modan, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Harefuah|November 15, 1981
[Leukocyte adherence inhibition test and carcinoembryonic antigen in colorectal carcinoma]A Shani, Z Weissman, Z Cohen, et al.
The American Journal of Cardiology|February 1, 1991
Prognostic importance of delayed Q-wave evolution 3 to 24 hours after initiation of thrombolytic therapy for acute myocardial infarctionM J Eisenberg, G I Barbash, H Hod, et al.
The American Journal of Cardiology|July 15, 1989
Intermittent, dose-related fluctuations of pain and ST elevation during infusion of recombinant tissue plasminogen activator during acute myocardial infarctionG I Barbash, H Hod, S Rath, et al.
Journal of the American College of Cardiology|April 1, 1990
Should thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot studyA Roth, G I Barbash, H Hod, et al.
British Heart Journal|October 1, 1990
Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial InfarctionG I Barbash, A Roth, H Hod, et al.
The American Journal of Cardiology|December 1, 1989
Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarctionG I Barbash, H Hod, A Roth, et al.
The American Journal of Cardiology|September 1, 1990
Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarctionG I Barbash, A Roth, H Hod, et al.
The American Journal of Cardiology|August 1, 1990
Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarctionG I Barbash, A Roth, H Hod, et al.
Circulation|November 1, 1993
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality StudyH D White, G I Barbash, M Modan, et al.
Archives of Internal Medicine|October 10, 1994
Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality TrialG I Barbash, H D White, M Modan, et al.
Pageof 19